We've been focused on the patient's voice since we were founded in 2017. Our white paper, co-authored with Thomas Smith, discusses how gaining a deep understanding of patients’ lived experiences equips researchers, healthcare providers, and manufacturers with better information with which to make decisions and developments that enhance patient outcomes. Read it here: https://hubs.ly/Q02KybsG0 #patientcenteredresearch #patientengagement
About us
We are a patient-centered research organization. At Vitaccess, we redefine the landscape of real-world evidence (RWE) generation through our groundbreaking Vitaccess Real™ platform. Powering your studies, our platform and our expert team enable you to gain deeper and faster insights into the impact of diseases and treatments in the real world. We are: Specialists in Real-World Primary Data Collection: We design and run studies collecting data directly from patients, caregivers, and clinicians, ensuring full study management. Patient-Centric: We prioritize multi-stakeholder co-creation with patient groups and clinical experts, ensuring an inclusive methodology and patient-relevant data collection. Our patient-centric research can help you generate data on caregiver burden, adherence, burden of illness, preferences and utilities, symptoms, patient experience, physical function, work productivity, treatment satisfaction, social function, functional status, quality of life, healthcare-related costs, out-of-pocket costs, health status and more.
- Website
-
https://vitaccess.com/
External link for Vitaccess
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2017
- Specialties
- market access, real-world evidence, BYOD, ePRO, HEOR, rare diseases, melanoma, Charcot Marie Tooth, localization, migraine, health economics, oncology, analytics, data, myasthenia gravis, orphan, Cystic fibrosis, alsp, pcor, and healthcare research
Products
Locations
-
Primary
2nd Floor Nucleus House, 2 Lower Mortlake Road,
Richmond
London, TW9 2JA, GB
Employees at Vitaccess
-
Mark Larkin PhD
Patient centric, tech forward data & analytics
-
Alessandro Scala
Managing Partner @ Advbeca | Capital Markets | M&A | Private Debt and Equity | Venture Capital and Strategy
-
Tsitsi Monera-Penduka, PhD
Loving God | Loving People | Showing up for all-things-Phyto🌿
-
Casey Quinn
Real world evidence, health economics and policy, financing.
Updates
-
If you missed our webinar, “What is the point of real-world evidence?”, you can watch it on demand on our website: https://hubs.ly/Q02KydYk0 Mark Larkin PhD and Akosua Ofori were joined by RWE expert, Jeff Trotter, to discuss why real-world evidence is increasingly being used in the healthcare industry. #keepingitreal #webinar #realworldevidence
-
-
We are experts in understanding, measuring, and articulating patient experience in the real world. See our brief "Challenge, Solution, Value" case studies for some examples: https://hubs.ly/Q02Kyfs20 #patientcenteredstudies #PCO
-
-
Anna Richards and Sam Llewellyn recently visited Boston to meet with our clients about exciting upcoming research - and shared some lovely pictures on their return!
Head of Commercial || Real World Evidence || Patient Research || Digital data capture || Linguistic validation specialist || at Vitaccess
Today, 19 August, is Patient Advocacy Day! And timely enough, we've just come back from a productive trip to Boston and Cambridge to help clients with a range of patient-centric solutions for real-world studies, where patient advocacy groups, representatives and patients themselves will be involved across the study lifecycle, from design to dissemination. Photos are just added in for fun (and to show off the beauty of Boston/Cambridge)- but doesn't Sam look like he'd fit right in at #MIT??
-
-
Check out this recent publication exploring the psychometric properties of MG-ADL items and the MG-ADL score in myasthenia gravis (MG), which includes data from the MyRealWorld MG dataset: https://hubs.ly/Q02LxN_d0 Vitaccess is the steward of the MyRealWorld MG dataset, which is available for industry-led and academic research. If you are interested in learning more MyRealWorld MG or exploring options for access to data from over 2,000 MG patients, visit our website: https://hubs.ly/Q02LxPbn0
-
This month, we've got the spotlight on Spinal Muscular Atrophy (SMA). Did you know that the symptomatic management of SMA includes - but is not limited to - physical therapy, occupational therapy, respiratory function monitoring, and nutritional status monitoring? Did you know that the first of three disease-modifying therapies currently approved by the FDA for SMA was approved in 2016? The burden of SMA can be significant, and research is ongoing to develop new treatments to improve symptoms and quality of life. Real-world data can be invaluable in demonstrating burden of illness and efficacy of existing and novel treatments. To find out how Vitaccess can support you in generating fit-for-purpose real-world evidence in SMA and other rare conditions, get in touch today at https://bit.ly/3AcuIkt
-
-
Sam Llewellyn, Associate Director, Patient-Centered Outcomes, and Octavia Borecka, PhD, Senior Research Associate, recently co-authored a publication titled "Real world effectiveness of guaifenesin ER in tackling mucus hypersecretion in stable chronic bronchitis". Check it out here: https://bit.ly/3AdRd8r For more Vitaccess publications, visit: https://bit.ly/3YxQMji
-
-
This Spinal Muscular Atrophy (SMA) awareness month, we are looking at the value of real-world evidence in demonstrating the safety and efficacy of therapies in the post-marketing environment. This 2024 publication by Gowda and colleagues describes the real-world use and impact of onasemnogene abeparvovec (Zolgensma) in 99 pediatric patients with SMA type 1: https://hubs.ly/Q02FNWWc0 At Vitaccess, we support our clients to meet their real-world evidence generation needs, pre- to post-marketing. To learn more, schedule a capabilities call with Anna Richards, Head of Commercial: https://hubs.ly/Q02FNWSq0
Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom
thelancet.com
-
Sally-Anne Vincent, Senior Consultant at Vitaccess will be moderating a panel on the accuracy of existing measurement tools in assessing health-related quality of life of informal caregivers at this year's ISPOR EU! Join Sally and the panellists - Alice Biggane, Fleur Chandler, and Jill Carlton - this November. https://bit.ly/46IhaJt
Are Existing Measurement Tools Accurately Measuring Health-Related Quality of Life of Informal Caregivers?
ispor.org
-
We are delighted to announce the launch of The Vitaccess Real MG Registry, a new patient-centric, tech forward registry designed to capture longitudinal observational data on myasthenia gravis, its treatment, and impact on symptoms, daily activities, and quality of life. The registry will link direct patient-reported data with data reported by healthcare professionals and from patients’ existing medical records. Adult patients with MG will be recruited to the registry in a number of ways. If you are interested in learning more about the registry – including whether you can be involved as a patient participant or as a neurologist treating MG patients in the community – please visit the registry’s informational site: https://bit.ly/3JM48A5. To speak with a member of our team, contact us at https://bit.ly/3QsH7G3.
-